Yohei Sawa Selected Research

3- (3- (4- (3- (glucopyranosyloxy)- 5- isopropyl- 1H- pyrazol- 4- ylmethyl)- 3- methylphenoxy)propylamino)propionamide

1/2020

Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yohei Sawa Research Topics

Disease

2	Cardiomyopathies (Cardiomyopathy) 01/2020 - 09/2018
2	Fibrosis (Cirrhosis) 01/2020 - 09/2018
1	Myocardial Infarction 01/2020
1	Heart Failure 01/2020
1	Ischemia 01/2020
1	Ventricular Remodeling 01/2020
1	Atrial Remodeling 01/2019
1	Cardiomegaly (Heart Hypertrophy) 09/2018
1	Hypertrophy 09/2018
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 09/2018
1	Body Weight (Weight, Body) 09/2018

Drug/Important Bio-Agent (IBA)

2	salicylhydroxamic acid (SHAM)IBA 01/2020 - 09/2018
1	3- (3- (4- (3- (glucopyranosyloxy)- 5- isopropyl- 1H- pyrazol- 4- ylmethyl)- 3- methylphenoxy)propylamino)propionamideIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	SodiumIBA 01/2020
1	SymportersIBA 01/2020
1	InflammasomesIBA 01/2019
1	Adrenergic Agents (Adrenergic Drugs)IBA 09/2018
1	Interleukin-18 (Interleukin 18)IBA 09/2018
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 09/2018
1	Sodium-Glucose Transporter 1IBA 09/2018

Therapy/Procedure

1	Therapeutics 01/2020